 
 1 
 
 
 
ED-HOME: A PI[INVESTIGATOR_386361] A HOMELESSNESS PREVENTION 
INTERVENTION FOR SUBSTANCE USING EMERGENCY DEPARTMENT PATIENTS  
 
 
Principal Investigator:   
[INVESTIGATOR_305050], MD, MHS 
NYU Langone Health  
Departments of Emergency Medicine & Population Health 
[ADDRESS_484228]; Room A -345 
[LOCATION_001], NY [ZIP_CODE] 
[EMAIL_5988]  
(212) 263 -5850  
NYULH Study Number:  s18-[ZIP_CODE]  
Funding Sponsor:  NIH/NIDA  
ClinicalTrials.gov 
Number  [STUDY_ID_REMOVED]  
Initial version: 3/2/19  
Amended:  9/24/19  
Amended:  3/18/2020  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health. Do not disclose or use except as authorized in 
writing by [CONTACT_156586]: 11 January 2019  

Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  2 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
  
 
 
Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), any other applicable US government research regulations, and 
institutional  research  policies  and procedures.  The Principal  Investigator  [INVESTIGATOR_58579], 
or changes to the protocol will take place without prior agreement from the sponsor and documented 
approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate 
hazard( s) to the trial participants.  All personnel  involved  in the conduct  of this study  have  completed  Human 
Subjects Protection Training.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  3 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
  
 
Table of Contents  
 
Protocol Summary  ................................ ................................ ................................ ................................ .........  8 
Schematic of Study Design  ................................ ................................ ................................ ..........................  8 
1 Key Roles  ................................ ................................ ................................ ................................ .............  10 
2 Introduction, Background Information and Scientific  Rationale  ................................ ...................  11 
2.1 Background Information and Relevant  Literature ................................ ................................ .........  11 
2.2 Rationale ................................ ................................ ................................ ................................ ....... 12 
2.3 Potential Risks & Benefits  ................................ ................................ ................................ ............  12 
2.3.1  Known Potential Risks  ................................ ................................ ............................  12 
2.3.2  Known Potential Benefits  ................................ ................................ ........................  12 
3 Objectives and Purpose  ................................ ................................ ................................ .....................  13 
3.1 Primary Objective  ................................ ................................ ................................ .........................  13 
3.2 Secondary Objectives (if applicable)  ................................ ................................ ............................  13 
4 Study Design and Endpoints  ................................ ................................ ................................ .............  13 
4.1 Description of Study  Design  ................................ ................................ ................................ .........  13 
4.2 Study  Endpoints  ................................ ................................ ................................ ...........................  13 
4.2.1  Primary Study Endpoints ................................ ................................ .........................  13 
4.2.2  Secondary Study Endpoints  ................................ ................................ ....................  14 
4.2.3  Exploratory Endpoints  ................................ ................................ .............................  14 
5 Study Enrollment and Withdrawal  ................................ ................................ ................................ ..... 14 
5.1 Inclusion Criteria  ................................ ................................ ................................ ...........................  14 
5.2 Exclusion Criteria  ................................ ................................ ................................ ..........................  14 
5.3 Vulnerable Subjects ................................ ................................ ................................ ......................  14 
5.4 Strategies for Recruitment and Retention  ................................ ................................ ....................  15 
5.4.1  Use of DataCore/Epic Information for Recruitment  Purposes ................................  16 
5.5 Duration of Study  Participation  ................................ ................................ ................................  16 
5.6 Total Number of Participants and Sites  ................................ ................................ ...................  16 
5.7 Participant Withdrawal or Termination  ................................ ................................ .....................  16 
5.7.1  Reasons for Withdrawal or  Termination  ................................ ..............................  16 
5.7.2  Handling of Participant Withdrawals or  Termination  ................................ ...........  16 
5.7.3  Premature Termination or Suspension of Study  ................................ .................  16 
6 Behavioral/Social  Intervention ................................ ................................ ................................ ...........  17 
6.1 Study Behavioral or Social Intervention(s)  Description  ................................ ...........................  [ADDRESS_484229] Compliance with Study  Intervention  ................................ . 19 
7 Study Procedures and Schedule  ................................ ................................ ................................ ....... 19 
7.1 Study  Procedures/Evaluations  ................................ ................................ ................................ . [ADDRESS_484230] of Care Study  Procedures  ................................ ................................ ... 20 
7.2 Laboratory Procedures/Evaluations  ................................ ................................ .........................  21 
7.3 Study  Schedule  ................................ ................................ ................................ ........................  21 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  4 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 7.3.1  Screening  ................................ ................................ ................................ .............  21 
7.3.2  Enrollment/Baseline  ................................ ................................ .............................  21 
Enrollment/Baseline Visit (Visit 1, Day 0)  ................................ ................................ ....... [ADDRESS_484231] 1 (Day 7 –10) ................................ ................................ ................  [ADDRESS_484232] 1.2 (as needed, 7 –[ADDRESS_484233] 1)  ..........  [ADDRESS_484234] 1.3 (as needed, 7 –[ADDRESS_484235] 1.2)  ....... [ADDRESS_484236] 2 (3 months after baseline) ................................ ..........................  [ADDRESS_484237] 3 (5 months after baseline) ................................ ..........................  22 
7.3.4  Final Study  Visit ................................ ................................ ................................ ... 22 
7.3.5  Withdrawal Visit  ................................ ................................ ................................ ... 22 
7.3.6  Unscheduled  Visit ................................ ................................ ................................  22 
7.4 Concomitant Medications, Treatments, and  Procedures  ................................ .........................  22 
7.5 Justification for Sensitive  Procedures  ................................ ................................ ......................  22 
7.5.1  Precautionary Medications, Treatments, and Procedures  ................................ . 23 
7.6 Prohibited Medications, Treatments, and Procedures  ................................ .............................  23 
7.7 Prophylactic Medications, Treatments, and Procedures  ................................ .........................  23 
7.8 Participant Access to Study Intervention at Study  Closure  ................................ .....................  23 
8 Assessment of  Safety  ................................ ................................ ................................ .........................  23 
8.1 Specification of Safety Parameters  ................................ ................................ ..........................  23 
8.1.1  Definition of Adverse Events (AE)  ................................ ................................ ....... 23 
8.1.2  Definition of Serious Adverse Events (SAE)  ................................ .......................  23 
Serious Adverse Event  ................................ ................................ ................................ ... 23 
8.1.3  Definition of Unanticipated Problems  (UP) ................................ .........................  24 
Unanticipated Problems Involving Risk to Subjects or Others  ................................ ...... 24 
8.2 Classification of an Adverse  Event  ................................ ................................ ..........................  24 
8.2.1  Severity of Event  ................................ ................................ ................................ . 24 
8.2.2  Relationship to Study  Intervention  ................................ ................................ ...... 24 
8.2.3  Expectedness  ................................ ................................ ................................ ...... 25 
8.3 Time Period and Frequency for Event Assessment and  Follow -Up ................................ ........  25 
8.4 Reporting Procedures – Notifying the  IRB ................................ ................................ ...............  25 
8.4.1  Adverse Event  Reporting  ................................ ................................ ........................  25 
8.4.2  Serious Adverse Event Reporting  ................................ ................................ ...........  25 
8.4.3  Unanticipated Problem Reporting  ................................ ................................ ...........  26 
8.4.4  Reporting of  Pregnancy  ................................ ................................ ..........................  26 
8.5 Reporting Procedures – Notifying the Study  Sponsor  ................................ .............................  26 
8.6 Reporting Procedures – Participating Investigators  ................................ ................................  26 
8.7 Study Halting  Rules  ................................ ................................ ................................ ..................  26 
8.8 Safety Oversight  ................................ ................................ ................................ .......................  26 
9 Clinical  Monitoring  ................................ ................................ ................................ ..............................  26 
10 Statistical Considerations  ................................ ................................ ................................ ..................  27 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  5 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 10.1 Statistical and Analytical Plans  ................................ ................................ ................................  27 
10.2 Statistical Hypotheses  ................................ ................................ ................................ ..............  27 
10.3 Analysis  Datasets  ................................ ................................ ................................ .....................  27 
10.4 Description of Statistical Methods  ................................ ................................ ............................  27 
10.4.1  General Approach  ................................ ................................ ...............................  27 
10.4.2  Analysis of the Primary Efficacy  Endpoint(s)  ................................ ......................  27 
10.4.3  Analysis of the Secondary  Endpoint(s)  ................................ ...............................  28 
10.4.4  Safety Analyses  ................................ ................................ ................................ ... 28 
10.4.5  Adherence and Retention  Analyses  ................................ ................................ .... 28 
10.4.6  Baseline Descriptive  Statistics  ................................ ................................ ............  28 
10.4.7  Planned Interim Analysis  ................................ ................................ .....................  28 
10. 4. 7. 1  Safety  Review  ................................ ................................ ................................ ... 28 
10. 4. 7. 2  Efficacy Review  ................................ ................................ ................................ . 28 
10.4.8  Additional Sub -Group Analyses  ................................ ................................ ..........  28 
10.4.9  Multiple  Comparison/Multiplicity  ................................ ................................ ..........  28 
10.4.10  Tabulation of Individual Response Data  ................................ .............................  28 
10.4.11  Exploratory Analyses  ................................ ................................ ...........................  28 
10.5 Sample Size  ................................ ................................ ................................ .............................  29 
10.6 Measures to Minimize  Bias ................................ ................................ ................................ ...... 29 
10.6.1  Enrollment/Randomization/Masking  Procedures  ................................ ................  29 
10.6.2  Evaluation of Success of Blinding  ................................ ................................ ....... 29 
10.6.3  Breaking the Study Blind/Participant  Code  ................................ .........................  29 
11 Source Documents and Access to Source  Data/Documents  ................................ .........................  29 
12 Quality Assurance and Quality  Control  ................................ ................................ ............................  29 
13 Ethics/Protection of Human  Subjects  ................................ ................................ ...............................  [ADDRESS_484238] ................................ ................................ ................................ ........  30 
13.3  Informed Consent Process  ................................ ................................ ................................ ...... 30 
13.3.1  Consent/Assent and Other Informational Documents Provided to  Participants  . [ADDRESS_484239]  Keepi[INVESTIGATOR_007]  ................................ ................................ ................................ .. 33 
14.1 Data Collection and Management  Responsibilities  ................................ ................................ . 33 
14.2 Study Records  Retention  ................................ ................................ ................................ .........  33 
14.3 Protocol Deviations  ................................ ................................ ................................ ..................  34 
14.4 Publication and Data Sharing Policy  ................................ ................................ ........................  34 
15 Study Finances  ................................ ................................ ................................ ................................ .... 34 
15.1 Funding Source  ................................ ................................ ................................ ........................  34 
15.2 Costs to the  Participant  ................................ ................................ ................................ ............  34 
15.3 Participant Reimbursements or Payments  ................................ ................................ ..............  34 
14 Study Administration  ................................ ................................ ................................ ..........................  35 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  6 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484240] Policy  ................................ ................................ ................................ ...................  35 
16 References  ................................ ................................ ................................ ................................ ...........  36 
17 Attachments  ................................ ................................ ................................ ................................ .........  38 
Attachment A  ................................ ................................ ................................ ................................ ................  39 
 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  7 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484241] of Abbreviations  
 
 
AE Adverse Event/Adverse Experience  
AES Adult Emergency Services (Bellevue Hospi[INVESTIGATOR_307])  
DSMB  Data and Safety Monitoring Board  
ED Emergency Department  
FFR Federal Financial Report  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
HRST  Homelessness Risk Screening Tool  
ICF Informed Consent Form  
IRB Institutional Review Board  
N Number (typi[INVESTIGATOR_33891])  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Subjects Research  
PES Pediatric Emergency Services (Bellevue Hospi[INVESTIGATOR_307])  
PI [INVESTIGATOR_386362]/Serious Adverse Experience  
SOP  Standard Operating Procedure  
UC Urgent Care (Bellevue Hospi[INVESTIGATOR_307])  
 
 
Throughout this document, attachments (e.g., study surveys and other instruments) are designated using  
underlined italic  font. 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  8 
Behavioral Intervention Template Version: 11 January 2019   
  
 
Protocol Summary  
 
Title ED-Home: A pi[INVESTIGATOR_158566] a  homelessness prevention intervention 
for substance using emergency department patients  
Short Title  ED-Home  
 
 
 
Brief Summary  This is a single -arm pi[INVESTIGATOR_386363] -risk patients 
in the Bellevue Hospi[INVESTIGATOR_3409] (ED). ED patients (n=40) 
found eligible for the study will complete a baseline survey and receive 
referrals to appropriate services, with a final six -month follow -up survey.  
Interi m contacts at [ADDRESS_484242] 
information. A chart review of participant Bellevue Hospi[INVESTIGATOR_386364] -month follow -up visit.  
Phase  N/A 
 
Objectives  The primary objective is to test the feasibility and acceptability of 
implementing a homelessness prevention intervention for ED patients with 
unhealthy alcohol or drug use who are at risk for homelessness.  
Methodology  Single -arm pi[INVESTIGATOR_386365] -post outcome measurement.  
 
Endpoint  Primary endpoints are feasibility of the study and intervention (e.g., 
participant satisfaction, ability to enroll participants, ability to contact 
[CONTACT_386409] -up time points). Exploratory outcomes include 6 -month 
housing and substance use measures.  
Study Duration  Approximately 1.5 years.  
Participant Duration  Participants will complete a final follow -up survey 6 months after 
enrollment/baseline visit.  
Duration of behavioral 
intervention  The intervention delivered by [CONTACT_386410] -time, in -person 
referrals (at the time of the baseline/enrollment ED visit) and up to 3 follow -up 
trouble shooting phone calls to occur within 3 months of the initial visit.  
 
 
Population  Adult (≥18 years old), ED patients with unhealthy alcohol or drug use who are 
not currently homeless but who are predicted to have a high risk of future 
homelessness. Patients must speak En glish, reside in NYC, not be critically 
ill, and not currently be incarcerated. Patients will not be excluded based on 
race or gender. Projected sample size: approximately n=40.  
Study Sites  NYULH and Bellevue Hospi[INVESTIGATOR_386366] 40 participants are expected to be enrolled.  
 
Description of Study 
Intervention/Procedure  The intervention will consist of: 1) Referral to Homebase homelessness 
prevention services offered by [CONTACT_29436] -based organizations in NYC; 2) 
Referral to substance use services (SBIRT and Addiction Leads) available at 
Bellevue Hospi[INVESTIGATOR_307]; 3) Follow -up to ensure participants receive needed 
services.  
Reference Therapy  Standard ED care, which includes referra l to the ED social worker and 
existing substance use treatment services at provider discretion.  
Key Procedures  No invasive procedures will be conducted.  
 
Statistical Analysis  Primary feasibility endpoints will be analyzed using descriptive statistics 
(proportions, means, etc.). Secondary/exploratory end -points will use 
appropriate comparisons of baseline and 6 -month follow -up data.  
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health. Do not disclose or use except as authorized in 
writing by [CONTACT_386411]: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  8 
Behavioral Intervention Template Version: 11 January 2019   
  
Schematic of Study Design  
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health. Do not disclose or use except as authorized in writing by [CONTACT_386412]: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  9  
  
 
 
 
ED-Home Pi[INVESTIGATOR_386367] -UP PROCEDURES
Locator form verification 
call (may need >1 call)
-Ask if referrals were successful
Note: Successful referral means participant went 
to Homebase and spoke with someone there 
about obtaining needed services
-Confirm date of 6 month follow -up visit
Troubleshoot, Determine next steps for 
connecting participant to services
7-10 daysIf referrals 
unsuccessful †
2ndFollow -up phone call: Check to see if 
participant accessed services  Document in 
REDCap
Appointment confirmation call or text
Check -in call or text
Follow -up survey
6 month follow -up visit
Participant receives incentiveIf no show
Call participant: 
Attempt to 
schedule make -up 
appointment for 6 
month follow -up 
(in person)If no show
3rdcall: Attempt to schedule 
make -up appointment —suggest 
conducting survey by [CONTACT_648]; 
arrange for incentive to be 
delivered
Document in 
REDCapDocument in 
REDCapDocument in 
REDCap
Continue to troubleshoot + 3rdfollow up phone 
callIf participant did not receive services
-Confirm date of 6 month follow -up visit
-Attempt to get new/updated contact 
[CONTACT_2997]
-Confirm date of 6 month follow -up visit
-Attempt to get new/updated contact 
[CONTACT_2997]
2ndcall: Attempt to 
schedule make -up 
appointment (in person )
If no show
-Mail 6 -month follow -up visit reminder 
letter 
Note: In the cases where participants aren’t able to be reached by [CONTACT_386413], we may also use email to contact [CONTACT_2299] . 
*Multiple attempts at each locator form location to reach participant .
†If participant has not been in contact [CONTACT_386414] , study staff will contact [CONTACT_386415]. 3 months*
6 months*
Window= -2 weeks to 
+8 weeks  
(Goal as close to 6 month 
mark as possible)5 months*7-10 days*
-Confirm participant’s phone numbers
 
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as authorized in writing by [CONTACT_305120]: 11 January 2019  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/[ADDRESS_484243], Room A -345 
[LOCATION_001], NY [ZIP_CODE] 
(212) 263 -5850  
[EMAIL_5988]  
 
Research Coordinator  
Daniela Fazio  
NYU Langone Health  
Associate Research Coordinator, Department of Emergency Medicine 
[ADDRESS_484244], Room A -345 
[LOCATION_001], NY [ZIP_CODE] 
(646) 501 -4034  
[EMAIL_7468]  
 
Study Sponsor/Program Officer  
Jacqueline Lloyd, PhD, MSW 
Deputy Branch Chief, NIDA 
[ADDRESS_484245]  
Rockville, Maryland [ZIP_CODE]  
(301) 443 -8892  
[EMAIL_7469]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health. Do not disclose or use except as authorized in 
writing by [CONTACT_156586]: 11 January 2019  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  11 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 2 Introduction, Background Information and Scientific  Rationale  
2.1 Background Information and Relevant  Literature  
 
Homelessness prevention: promise and challenges.  Evidence is mounting that timely yet relatively brief 
interventions can prev ent people from having to enter a homeless shelter.1,[ADDRESS_484246] e who are 
unaware of or unable to access such services.9 
 
Emergency departments as sites for homelessness risk screening and prevention.  The emergency 
department  (ED) may be an ideal  location  for homelessness  risk screening  and prevention,  reaching  people 
who are at high risk for homelessness  and who might  not otherwise  access  specialized  prevention  services. 
The Veterans  Health  Affairs  system  has implemented  universal  homelessness  screening  and referral  in its 
clinics,7 yet no research  has explored  homelessness  prevention  among  ED patients.  More  than 130 million 
visits are made to U.S. EDs each year.14 As the health care “safety net,” EDs care for the most vulnerable 
populations  in our society.15-[ADDRESS_484247] during health crises, but also during life crises. A VA study found a statistically significant increase in 
the number of ED visits veterans make in the 30 days prior to becoming homeless.20 A study of new 
homeless shelter entrants in [LOCATION_001] found that 34% had used an ED in the past year.21 A disproportionate  
share  of ED patients  are homeless22-24 or at risk for homelessnes s. For example,  a survey of  all patients  
presenting  over 24 hours  in three  Michigan  EDs found  that 3.5%  had been  evicted  in the past year and 16% 
lived in crowded housing.16 A survey of 1,500 Philadelphia ED patients found that 18.1% reported housing 
insta bility.[ADDRESS_484248] found high levels of food insecurity, low income, and other 
risk factors for homelessness.16,25 -28 In a preliminary study of 625 randomly selected Bellevue  Hospi[INVESTIGATOR_386368] 3 months,  30.5%  had a history  of homelessness in  their lifetimes  and 
19.8%  had been  homeless  in the past year.  Among  those  not currently  homeless,  18% were worried about 
having stable housing in the next 2 months. Further, 9.1% had been evicted at least once  in the past  year.  
 
ED patients  with unhealthy  alcohol  or drug use may be at even  higher  risk of homelessness  than other  ED 
patients  given  the strong  associations  between  homelessness  and substance  use. One study  of 19,055  ED 
patients  found  that those  who screened  positive  for substance  use had very high rates  of homelessness  or 
unstable housing: 22.8% were currently living in a shelter or on the streets and an additional 36.1% were 
“doubled up” with family or friends.[ADDRESS_484249] the potential to reach more people —and pote ntially more vulnerable people40—than 
interventions at other  sites.  
 
Summary.  EDs have potential as important health care delivery settings for homelessness prevention 
efforts among all patients, and particularly among patients with unhealthy alcohol or dr ug use. In earlier 
research, we developed an empi[INVESTIGATOR_3675] -based homelessness risk screening tool (HRST) to identify ED 
patients at high risk for future shelter entry. We also conducted qualitative interviews with ED patients to 
learn about their pathways to  homelessness and thoughts about future homelessness prevention  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  12 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484250] step in expanding 
our knowledge and de termining whether and how future interventions and studies will be possible. Given 
that this is a feasibility study, the choice of a single -arm study (intervention arm only) is appropriate. This 
feasibility  study  will inform  a larger  future  trial of homele ssness  prevention  interventions  for substance  using 
ED patients.  Attempting  to prevent  homelessness  among  ED patients  is important  for the reasons  stated  in 
section  2.1. 
 
2.3 Potential Risks & Benefits  
 
2.3.[ADDRESS_484251] health care services, and potential breach of  confidentiality.  
 
1. Discomfort  associated  with answering  personal  questions  during  study  surveys/assessments  (immediate 
risk): Participants will complete surveys that include questions on health status, mental health, substance 
abuse, socioeconomic status, homelessness and housing, and other topi[INVESTIGATOR_386369]. In the informed consent process, participants will be instructed that they can divul ge 
as little or as much  as they choose  and are free to withdraw  from the study  at any time and for any reason.  
 
2. Fear that refusal  to participate  will affect  care or services  (immediate  risk):  Given  that participants  will be 
recruited  while  they are patients  in the Bellevue  Hospi[INVESTIGATOR_386370], they may fear that refusal  to participate  in the 
study will adversely affect the care they receive. This risk is minimal because research staff who will be 
enrolling  patients  into the study  are not part of the patients ’ treatment  teams,  and it will be clearly  explained 
to potential participants that refusal to participate will in no way affect their care in the Bellevue Hospi[INVESTIGATOR_386371]. 
 
3. Potential breaches of confidentiality (immediate and long -term risk): There is a small risk of breach of 
confidentiality. A breach of confidentiality could potentially be damaging to study subjects if personally 
identifying information was released along with their answers to the baseline surveys. Such a breach is 
improbable, however, because of the safeguards that will be taken around the storage of personally 
identifying  information.  
 
Given the steps that we will take to minimize the chances of breach of confidentiality and other risks, 
participating  in this study  presents  low risk and thus the risk/benefit  ratio is favorable,  particularly  given  the 
potential benefits to participants described below. Further, the knowledge gained from the proposed 
research has the potential to benefit future ED patients who are at risk for  homelessness . 
 
2.3.2 Known Potential Benefits  
All participants in the study will receive an intervention that includes: 1) Referral to Homebase 
homelessness prevention services offered by [CONTACT_29436] -based organizations in NYC; 2) Referral to 
substance use services (SBIRT and  Addiction Leads / peer counselor) available at Bellevue Hospi[INVESTIGATOR_307]; 3)  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  13 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 Follow -up to ensure patients receive needed services. A prior randomized controlled trial showed that 
people receiving Homebase services in NYC had lower risk of entering a homeless shelter in the future.11 
Therefore,  one potential  benefit  to pi[INVESTIGATOR_386372]—and if they go and 
are found  eligible  will receive —services  that may reduce  their risk for future  homelessness.  Participants  will 
also receive referrals to appropriate substance use services that are already offered at the study hospi[INVESTIGATOR_307], 
including SBIRT (screening, brief intervention, and referral to treatment) and peer navigator/social work 
services (Addiction Leads). Prior research has suggested that receipt of such services in the ED may 
improve substance use related outcomes for some patients, particularly those with unhealthy alcohol 
use.31,41,[ADDRESS_484252] the feasibility  and acceptability  of implementing  a homelessness 
prevention  intervention  for ED patients  with unhealthy  alcohol  or drug use who are at risk for homelessness. 
Accomplishing  this objective  will allow  us to modify  the intervention  and study  designs  to be proposed  for a 
future larger, multisite study that will include testing for  outcomes/efficacy.  
 
3.[ADDRESS_484253] the feasibility  and acceptability  of implementing  a homelessness 
prevention  intervention  for ED patients  with unhealthy  alcohol  or drug use who are at risk for homelessness.  
 
3.2 Secondary Objectives (if applicable)  
Not applicable.  
 
[ADDRESS_484254] a single -arm (intervention only) pi[INVESTIGATOR_158566] a homelessness prevention and 
substance use intervention for Bellevue Hospi[INVESTIGATOR_386373], with longitudinal foll ow-up to 6 months after the baseline visit.  
 
4.2 Study  Endpoints  
 
4.2.1 Primary Study Endpoints  
Given  the primary  study  objective  around  feasibility  and acceptability,  the primary  study  endpoints  represent 
a constellation of feasibility and acceptability measures that will be informative in modifying/developi[INVESTIGATOR_007] a 
future larger intervention study. We will track the number of patients approached, the number screening 
positive for unhealthy alcohol or drug use, the number screening positive for homelessness risk, and the 
number of those eligible for the intervention who agree to participate. We will track reasons for study 
ineligibility and refusal, and will compare basic characteristics (e.g., gender, age, race, drug and alcohol 
use) of those wh o agreed and did not agree to participate. We will also track the number and location of 
referrals made for homelessness prevention and/or substance use services, the number of appointments 
kept, the number and types of homelessness prevention and other se rvices actually received, and the 
length of time between the ED intervention and receipt of services. We will track the ability to contact 
[CONTACT_386416] 6-month  follow -up interview  (e.g.,  number  of calls needed).  Data  sources  for these  feasibility 
endpo ints include the ED-Home Baseline Screening and Survey  (see attachment) and the participant 
tracking and follow -up information that will be documented on REDCap ( ED-Home Follow -up Procedures  
Form  and ED-Home  Tracking  Form ) and using  a tracking  log in Excel  that will be used  internally  to manage 
participant status, attempts of contact [CONTACT_20688], attempts of contact [CONTACT_386417], and necessary 
follow -up steps; no protected health information will be recorded on the Excel tracking log. In additi on, we 
will gather  information  on acceptability  of and satisfaction  with both the overall  intervention  and its individual 
components  from patients  both immediately  after the intervention  is provided  (while  they are in the ED) and 
at the 6-month  follow -up interview  using  a series  of intervention  assessment  questions  contained  in the 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  14 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 baseline and follow -up surveys (see ED-Home Baseline Screening and Survey  and ED-Home 6 -Month  
Follow -up Survey ). At the 6 month follow -up interview, as part of the  ED-Home 6 -Month Follow -up Survey , 
we will use the Housing Risk Flyer  as well as a  NYC HRA YouTube video. We will also speak with 
stakeholders (e.g., ED providers, homelessness prevention service providers) to obtain feedback on the 
intervention and factor s to enhance its future implementation and sustainability.  
 
4.2.2 Secondary Study Endpoints  
Not applicable.  
 
4.2.3 Exploratory Endpoints  
Exploratory outcomes will include new onset homelessness as measured by [CONTACT_386418] a homeless shelter 
within 6 months of the ED int ervention (determined using the Department of Social Services CARES 
database), multiple self -reported housing status and substance use measures at the 6 -month follow -up 
interview  (see ED-Home  6 Month  Follow -Up Survey  and Additional  Baseline  and Follow -up Questionnaires  
attachments), and measures of health services use (see ED-Home EMR Data Abstraction Tool ). Although 
we are not powering  the study  to show  statistically  significant  effects  on these  outcomes,  we will be able to 
determine  feasibility  of outcome  measurement  and gain a preliminary  sense  of potential  intervention  effects.  
 
[ADDRESS_484255] meet all of the following criteria:  
1. Be a patient  in the Bellevue  Hospi[INVESTIGATOR_386374] (including  the Adult  Emergency  Services, 
Pediatric Emergency Services if ≥18 years old, and Urgent  Care).  
2. Be ≥18 years  old. 
3. Screen positive for homelessness risk using the homelessness risk screenin g tool  (HRST).  
4. Screen positive for unhealthy alcohol or drug  use. 
5. Able and willing to provide  consent.  
 
All participants must be able to and agree to provide informed consent to study participation.  
 
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. Medically (e.g., critically ill) or psychiatrically  unstable.  
2. Unable to provide informed consent for other reason (e.g., dementia or other cognitive deficit, 
profound  intoxication).  
3. Incarcerated or in police custody.  
4. Unable to understand and speak  English.  
5. Lives outside NYC and/or cannot give a NYC ZIP  code.  
6. Already homeless (residing in a shelter or on the  streets).  
7. Does not have a telephone where can be reached for  follow -up. 
8. Has already received specialized peer navigator/addiction social worker services (Addiction 
LEADs) during current ED  visit. 
9. Has already participated in the  study.  
 
Non-English speaking patients are being excluded because English -speakers are at highest risk fo r 
shelter entry in [LOCATION_001] City, and our primary patients of interest for this intervention are those at 
risk for shelter entry. Limited resources for this small pi[INVESTIGATOR_386375].  
 
5.3 Vulnerable Subjects  
Children  under  the age of 18 will be excluded  from the study.  Pregnant  women  will not be excluded  because 
pregnancy  is a known  risk factor  for future  homelessness.  This research  does  not pose  any risk to the fetus. 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  15 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484256] participants found to be eligible for the study will be from 
socioeconomically disadvantaged groups, as the study is targe ted to patients who are at risk for future 
homelessness. Further information on potential risks and benefits appears in section  2.3. 
 
5.4 Strategies for Recruitment and Retention  
Study participants will be recruited exclusively in the Bellevue Hospi[INVESTIGATOR_38519] (inc luding AES, PES, and UC). 
ED patients  will be approached  by [CONTACT_386419]  (see ED-Home  Baseline 
Procedures flow chart in Schematic of Study Design section). Patients will only be approached during 
periods when they are n ot receiving active clinical care (e.g., RAs will not interrupt if a doctor or nurse is 
talking  with the patient).  Patients  who are medically  or psychiatrically  unstable  will also not be approached.  
 
We will use a random  sampling  scheme  of adult  ED patients.  Trained  Research  Assistants  (RAs)  will begin 
each  shift in a randomly  assigned  section  of the ED to start patient  recruitment  for the shift (these  sections 
include the “sides” of the AES, the UC, and the PES). The RA will then approach patients s equentially 
beginning with a random first patient in the randomly assigned patient area and moving systematically 
through sequential areas of the ED once covering the initial area. RAs may use the publically displayed 
“white  boards”  located  in all sections  of the ED to assist  in identifying  appropriate  patients  for screening;  for 
example, the “white boards” display patient age and location, which will assist RAs in identifying patients 
who are ≥18 years old. In addition to the random sampling scheme  as described above, it is possible that 
ED care providers may identify specific patients who they feel would benefit from the study and may ask 
RAs to screen those patients for eligibility. In those cases, the RA/RC can break the random sampling 
scheme  but will make  a note in REDCap  that this was done  so that we can track  recruitment  processes  for 
our feasibility study  outcomes.  
 
Study  procedures  including  screening  and informed  consent  will occur  in the Bellevue  Hospi[INVESTIGATOR_386370]. Multiple 
steps  will be taken  to maximize  patient  privacy,  including:  asking  any visitors  to leave  the room/area;  moving 
patients to private or semi -private areas of the ED when feasible; speaking in a low voice near patients’ 
heads.  
 
Upon approaching patients, RAs will explain that they are conducting a research study and obtain patient 
verbal assent to complete screening questions for study eligibility. A standard screening tool will be used, 
with RAs guided through the screening and entering question responses in real -time using REDCap (see 
ED-Home  Baseline  Screening  and Survey  attachment).  Patients  who are found  eligible  for the study  will be 
invited to participate. The informed consent process will be conducted by [CONTACT_386420], what information they will be asked to give, and who 
receives and can use this information (see ED-Home Informed Consent  and ED-Home Key Information  
Sheet attachment). Written informed consent is required for study participation. Participants will sign two 
consent forms; one copy to retain themselves and the other for study records. For participants in whom 
capacity  to complete  informed  consent  is questionable,  a validated  consent  capacity  quiz will be completed 
(see ED-Home UBACC  attachment) and/or research staff will discuss with the patient’s treating provider 
prior to obtaining written informed  consent.  
 
Participant retention will be enhanced in the following ways:  
- Detailed locator information will be collected from each participant. This information will include 
multiple contact [CONTACT_386421] -up procedures.  See ED-Home  Locator  Form  attachment  for full details.  
- Participants will be given a study contact [CONTACT_386422], for example, if their contact [CONTACT_386423]. See ED-Home 
Study Contact [CONTACT_386424].  
- Follow -up participant cont act including follow -up visit reminders will occur in the manner and 
schedule  outlined  in the ED-Home  Baseline  Procedures  flow chart  in the Schematic  of Study 
Design  section.  
 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  16 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 5.4.1 Use of DataCore/Epic Information for Recruitment  Purposes  
Not appl icable.  
 
5.5 Duration of Study  Participation  
The duration of active study participation is approximately 6 months, with the final follow -up survey with 
patients occurring 6 months after baseline/enrollment. In cases in which it is difficult to contact [CONTACT_386425] -up survey, th e follow -up visit may be conducted up to 2 months after the 6 
month follow -up time period (i.e., up to 8 months after study enrollment). See the ED-Home Pi[INVESTIGATOR_386376] - 
Up Procedures flow chart  in the Study Schema section for details.  
 
5.6 Total Number of Participants and Sites  
We plan to enroll approximately 40 participants at a single site (Bellevue Hospi[INVESTIGATOR_386377]). If there are 
multiple participants who drop out of the study after being consented and/or who cannot be reached for 
follow -up procedures,  we may recruit additional participants as needed to achieve the primary study 
endpoints.  
 
5.[ADDRESS_484257], which can be 
made in writing or verbally to the study PI.  
 
Investigators may terminate participation in the study if:  
• Any clinical adverse event (AE) or situation occurs such that continued participation in the study 
would not be in the best inte rest of the  participant.  
• It is discovered that participant lacks cognitive or mental capacity to understand the study, 
whether lacking such capacity at the time of initial consent (unidentified at the time) or  during 
follow -up procedures.  
 
In the case of p articipant withdrawal or termination, information already collected from the participant will 
still be used for the purposes of the study unless:  
• The study participant explicitly revokes consent to use his/her information for the study, either in 
writing or verbally to the study PI;  or, 
• It is determined that the original study consent was not valid (for example, in a case where it is 
determined that the study participant likely did not have capacity to provide informed consent at 
the time it was in itially  conducted).  
 
5.7.2  Handling of Participant Withdrawals or  Termination  
There are no risks to participants from withdrawing from the study or termination of participation. As noted 
above, participants will be asked if investigators can continue to use info rmation already collected from 
them for the purposes of the study, including use of their personally identifying information to examine 
outcomes in data sources specified in the informed consent form (including Department of Homeless 
Services data and Bell evue Hospi[INVESTIGATOR_386378]). No additional information will be 
collected from participants themselves after withdrawal or termination from the study.  
 
As this is a feasibility study, if fewer than five participants withdraw or are termina ted from the study they 
will not be replaced. If five or more participants withdraw or are terminated from the study, study 
enrollment may be increased to replace them in order to achieve adequate ability to examine the primary 
feasibility outcomes.  
 
5.7.3  Prema ture Termination or Suspension of Study  
Premature termination or suspension of the study is not expected.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  17 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause. If the study is prematurely t erminated or suspended, the PI [INVESTIGATOR_386379], and will provide the reason(s) for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to  participants  
• Insufficient compliance to protocol  requirements  
• Data that are not sufficiently complete and/or  evaluable  
• Lack of adequate funding to complete the  study  
None of the above are expected to occur for this small feasibility pi[INVESTIGATOR_799].  
 
The study may resume once concerns about safety, protocol compliance, and/or data quality are 
addressed and satisfy the sponsor and/or IRB.  
 
6 Behavioral/Social  Intervention  
6.1 Study Behavioral or Social Interventi on(s)  Description  
The intervention will consist of:  
1) Referral to Homebase homelessness prevention services offered by [CONTACT_29436] -based 
organizations in  NYC;  
2) Referral to substance use services (SBIRT and Addiction Leads) available at Bellevue  Hospi[INVESTIGATOR_307];  
3) Follow -up to ensure participants receive needed services. 
Each of these components is described in more detail  below.  
 
Referral to Homebase homelessness prevention services  
Homebase is the homelessness prevention program offered by [CONTACT_386426]. It 
has been found in prior research to be effective in reducing future shelter entries among [LOCATION_001]ers at 
risk for homelessness.  Homebase  services  are tailored  to individual  needs  and may include  assistance  with 
landlord -tenant mediation, assistance in paying rental arrears, other financial assistance, assistance with 
benefits  applications  (e.g.,  SNAP),  family  mediation,  and other  services.  Upon  initial  arrival  to a Homebase 
office, clients are assessed for Homeba se service eligibility by a case worker. Eligible clients are assigned 
to a case worker and receive services. Homebase services are currently provided by [CONTACT_386427],  at more  than fifteen  different  locations  spread  throughout  the city; 
the specific location at which clients will be served depends on their zip  code.  
 
Study staff will determine to which Homebase office to refer study participants based on their zip code. 
Study  staff will write  down  the name,  location,  hours,  and contact  [CONTACT_386428]. Study staff will also provide study participants with an 
informational  handout  on Homebase  (see ED-Home  Homebase  Information  Sheet  attachment).  Study  staff 
will make the referral to Homebase using an ED-Home Homebase Referral Form for Bellevue Pi[INVESTIGATOR_386380] e-mailed  to the appropriate  Homebase  office  as well as to related  staff from the NYC  Department  of 
Social Services (see ED-Home Email Template for Homebase ). This referral form was developed in 
conjunction with a pi[INVESTIGATOR_386381]. The Homebase providers are asked to reply to study staff by e-mail within [ADDRESS_484258]  the participant  within  1 week  either  by [CONTACT_386429], and reply to study staff by e -mail within 6 weeks to confirm whether the client 
was enrolled, declined to enroll, or was unable to be enrolled in Homebase services. Additionally, study 
staff may communicate with Homebase staff and/or the NYC Department of Social Services (including 
Human Resources Administration Prevention & Community Services) by [CONTACT_17084]/or NYULH SendSafe 
email to facilitate if the participant has not been in contact [CONTACT_386430].  A successful  referral  would  mean  that the participant  went  to Homebase  and spoke 
with someone there about obtaining needed  services.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  18 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 Referral to substance use services  
Bellevue Hospi[INVESTIGATOR_386382] (Screening, Brief Intervention,  and Referral to Treatment) 
services for emergency department patients. These services are free of charge and are available to all 
patients during times when SBIRT staff are present. SBIRT services have been described in the prior 
literature. In brief, the y consist of assessing patients’ substance use, offering a brief intervention using 
principles of harm reduction and motivational interviewing, and referring patients to substance use 
treatment  as appropriate.  By [CONTACT_5942],  these  services  are tailored  based  on individual  needs.  Participants 
may be provided with brochures or other written material about substance use as appropriate for the 
individual.  All SBIRT  providers  have  been  trained  in SBIRT  procedures.  SBIRT  is provided  as part of routine  
ED care, separate from this  study.  
 
The Bellevue Hospi[INVESTIGATOR_386383], which 
consists of a peer counselor/social worker team. These services are also free of charge and are available 
to patients who need them during the hours in which the peer counselor/social worker are available. This 
is a new program  at Bellevue  Hospi[INVESTIGATOR_307].  As such,  the exact  services  that will be provided  may vary somewhat 
during  the study  time period  but will consist  of assessing  patients’  substance  use, counseling  patients  about 
their substance use, connecting patients with medication therapy for substance use as appropriate 
(including via prescriptions given by [CONTACT_386431]), and connecting patients with outpatient or inpatient 
substance  use treatment  referrals  as appropriate.  Patients  may be provided  with brochures  or other  written 
material about substance use as appropriate for the  individual.  
 
The role of the study  staff will be to contact  [CONTACT_386432]/or  Addiction  Leads  teams  during  the participant’s 
baseline ED visit. The SBIRT and/or Addiction Leads teams will then assess and provide services to the 
participant during the baseline ED visit. The exact services provided will depend on participant needs, as  
these are designed to be individually tailored services. Of note, both of these programs are considered to 
be standard of care in the ED; study staff will simply facilitate by [CONTACT_386433]. Participants will be referred to one or both of these 
substance  use services  depending  on availability  of service  staff,  participant  need,  and participant  interest.  
 
 
6.1.1 Administration of  Intervention  
Referral  to Homebase  will be provided  in-person  by [CONTACT_386434]. Participants will be encouraged by [CONTACT_386435]; some Homebase offices may accept appointments and others 
operate  on a walk-in basis.  Homebase  services  are generally  provided  in-person  at the Homebase  offices, 
though some services may also be provided by [CONTACT_386436]. The frequency, mode, and duration of 
contact [CONTACT_386437], and is likely to vary 
depending on individuals’  needs.  
 
Referral to substance use services will be provided in -person by [CONTACT_386438]. The SBIRT 
and Addiction Leads teams will provide  services as detailed above in -person during the baseline ED visit. 
Follow -up services will depend on the individual needs of the participant and may include follow -up phone 
calls to check on progress. Participants may also be referred to other services, s uch as outpatient clinics 
for substance use or inpatient substance use treatment programs. The exact services, timing, frequency, 
mode, and duration will depend on individual participant needs.  
 
Follow -up by [CONTACT_386439].  Study  staff 
will talk with participants  to help facilitate  service  receipt  by [CONTACT_386440],  using  the schedule  as 
outlined  in the Schematic  of Study  Design  Section  (Follow -Up Procedures  Flow  Chart).  In the cases  where 
participants aren’t able to be reached by [CONTACT_386441], 
we may also use a study NYULH SendSafe email to contact [CONTACT_2299]. Additionally, if we are unable 
to rea ch the participant, and the participant has given us permission to do so, we may contact [CONTACT_2416]’s  place  of work,  health  care providers,  case  workers/social  workers,  or substance  use treatment 
programs that they attend. Study staff will also commun icate with staff from Homebase and the NYC 
Department of Social Services as needed to facilitate  referrals.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  19 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484259] received as a result of study intervention referrals, and the results of those referrals. 
This information will be based primarily on participant self -report,  with additional information obtained from 
Homebase staff as  needed.  
 
7 Study Procedures and Schedule  
7.1 Study  Procedures/Evaluations  
 
7.1.1  Study Specific Procedures  
Study procedures are outlined in the two flow charts in the Schematic of Study Design section. These 
procedures include:  
• Screening  for study  eligibility,  informed  consent  process  for eligible  and interested  patients 
(baseline).  
o For patients who may be homeless or at risk for homelessness but not eligible for the 
study, RAs will offer the patient a resource sheet (see Housing Resource  Sheet ). 
• Survey (to be administered at baseline and 6 month follow -up visits): verbally administer ed 
survey to collect participant satisfaction information on intervention components and participant 
information including sociodemographics, physical and mental health, housing history, substance 
use history, criminal justice history, social support and s ocial determinants of health.  See specific 
instruments (attachments) for  details:  
o ED-Home Baseline Screening and Survey  (to be administered on REDCap)  
o ED-Home 6 Month Follow -Up Survey  (to be administered on  REDCap)  
• As part of the ED-Home 6 Month Follow -Up Survey , we will show participants 
the Housing Risk Flyer  (administered on paper)  which highlights certain risk 
factors for losing housing. We will then ask participants a series of questions 
about what they thought of the flyer.  
• As part of the ED-Home 6 Mo nth Follow -Up Survey , we will show participants 
a NYC HRA YouTube video  (administered on YouTube on study iPad)  about 
a woman who successfully connected to Homebase. We will then ask 
participants a series of questions about what they though t of the video . 
o Additional Baseline and Follow -up Questionnaires administered on paper : alcohol 
timeline follow -back; residential timeline follow -back;  WHO -ASSIST.  
• Participant information form (baseline only): collects name, date of birth, SSN (if applicable) to 
allow  future linkage  with NYC  DSS CARES  database  and Bellevue  Hospi[INVESTIGATOR_386384]  (ED- 
Home Participant Information Form ). 
• Intervention (begins at baseline): detailed in Section 6.1.  Includes:  
o Homebase referral (baseline only): contains participant basic information and is e -mailed 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  20 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 to the appropriate  Homebase  office  (ED-Home  Homebase  Referral  Form  for Bellevue  Pi[INVESTIGATOR_2268]) 
o Homebase information sheet (baseline only): contains name, location, hours, and contact 
[CONTACT_386442]. 
This referral information will be given to the participants ( ED-Home Homebase 
Information Sheet).  
o SBIRT (Screening, Brief Intervention, and Referral t o Treatment) and/or Addiction Leads 
services for substance use in ED (as detailed in Section  6) 
• Locator form (baseline only): collects detailed contact [CONTACT_386443] -up (ED-Home Locator Form ). 
• Study contact [CONTACT_1137] a nd sticker (baseline only): serves as a reminder for the participant’s [ADDRESS_484260] study staff 
proactively as needed (ED-Home Study Contact [CONTACT_386444]).  
• Follow -up phone  calls to confirm participant contact [CONTACT_3031], confirm follow -up appointment, 
and reschedule missed visits (see ED -Home Follow -Up Procedures Flow Chart in Schematic of 
Study  Design  section),  documented  in REDCap  (ED-Home  Tracking  Form  and ED-Home  Follo w- 
up Procedures Form)  and tracked using an Excel tracking log for internal study management 
purposes.  
• Follow -up phone  calls and/or  NYULH  SendSafe  emails  with participants  and service  providers 
(e.g., Homebase) to confirm referrals successful and troubleshoot as needed (see ED -Home 
Follow -Up Procedures Flow Chart in Schematic of Study Design section), documented in 
REDCap ( ED- Home Tracking Form  and ED-Home Follow -up Procedures Form)  and tracked 
using an Excel tracking log for internal study manage ment  purposes.  
• Mailing a follow -up visit reminder letter containing details of the participant’s appointment, 
documented  in REDCap  (ED-Home  Follow -up Visit Reminder  Letter  and ED-Home  Follow -up 
Procedures Form ). 
• Electronic medical record review for Bellevue Hospi[INVESTIGATOR_386385], 
inpatient  hospi[INVESTIGATOR_602],  outpatient  visits,  and substance  use service  visits  at Bellevue  Hospi[INVESTIGATOR_307] 
(ED-Home EMR Data Abstraction Tool ). 
• Via NYC governmental agencies (NYC Department of Social Services and/or NYC CIDI), review 
of CARES database (with consent of participants) for data on participants’ homeless shelter use, 
including dates and types of shelter use prior and subsequent to study enrollment. NYC DSS — 
which administers the Homebase pr ogram to which we are referring participants as part of the 
intervention —has agreed to inform us of the outcomes of our referrals (either directly or via their 
contracted agencies), including whether the participants enter a homeless shelter, for participa nts 
who have provided consent. NYULH researchers will not be directly accessing outside 
databases.  
 
7.1.[ADDRESS_484261]  clinical  care that patients  receive  while  in the ED. The referral 
to substa nce use services (SBIRT and Addiction Leads) are part of standard care offered in the ED during 
times in which these programs operate. In general, SBIRT and Addiction Leads staff actively screen patients 
in the ED to identify patients in need of their serv ices. In addition, clinical staff (e.g., nurses, physicians) can 
refer patients to SBIRT and Addiction Leads programs based on their clinical judgment of need. The SBIRT 
and Addiction Leads services that will be offered to study participants are the same a s those offered as part 
of routine clinical care; the only difference is that for the study our study staff will facilitate real -time referrals 
for participants to ensure that participants receive these ED -based services. Therefore, any referrals, 
treatmen ts (including assistance in obtaining medication treatment), or other services  provided  as part of 
SBIRT  or Addiction  Leads  referrals  will be considered  to be part of standard  of care in the ED, not unique 
services offered through the  study.  
 
Other  referrals  as part of the study  (e.g.,  to Homebase)  are not currently  part of routine/standard  of care in 
the ED, though currently ED care providers refer patients to social workers on an ad hoc basis as needed 
to assist with housing and homelessness concer ns. Our study referral to Homebase represents an 
enhancement in the standard of care since currently social work services in the ED for 
housing/homelessness are quite limited in  scope.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  21 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
  
7.2 Laboratory Procedures/Evaluations  
Not applicable.  
 
7.3 Study  Schedule  
Full details on the study schedule, including all baseline and follow -up procedures, are provided in the 
Schematic of Study Design figures presented near the beginning of this protocol.  
 
7.3.1  Screening  
Screening for study eligibility will occur during a patient’s Bellevue Hospi[INVESTIGATOR_386386]. The process for 
screening is provided in the ED-Home Pi[INVESTIGATOR_386387].  The process  for screening  is fully described  in protocol  Section  5.4 and the attachment  ED- 
Home Baseline Screening and Survey . 
 
7.3.2  Enrollment/Baseline  
The baseline/enrollment visit will occur during the same ED visit as screening. All baseline procedures will 
occur during this visit. Research staff will confirm eligibility for the st udy by [CONTACT_386445].  The sequence  of baseline  visit events 
is outlined in the ED -Home Pi[INVESTIGATOR_386388].  
 
Enrollment/Baseline Visit (Visit 1, Day 0)  
• Verify inclusion/exclusion  criteria.  
o If patient may be homeless or at risk for homelessness but not eligible for the study, give 
homelessness resource  sheet . 
• Verify patient has not already participated in the  study.  
• Explain the study. Obtain informed consent of potential participant verified by [CONTACT_125781]. One copy of completed informed consent form will be given to participant 
and the other copy retained for study  records.  
• Complete baseline survey and supp lemental questionnaires (see instruments as listed in Section 
7.1.1).  
• Complete participant information form (see Section  7.1.1).  
• Real-time referral to substance use services to be provided during baseline visit (SBIRT and/or 
Addiction Leads).  
• Referral for Homebase homelessness prevention  services.  
• Complete Participant Locator Form (see Section  7.1.1).  
• Schedule follow -up appointment and give appointment using study contact [CONTACT_386446].  
• Participant given $[ADDRESS_484262].  
 
7.3.3  Intermediate Visits  
Intermediate “visits” will occur via phone as outlined in the ED -Home Follow -Up Procedures Flow Chart in 
the Study Schema section. In the cases where participants aren’t able to be reached by [CONTACT_386447],  we may also use a study  NYULH  SendSafe  email  to contact 
[CONTACT_2299]. Additionally, only if we are unable to reach the participant directly and if the participant has 
given us permission to do so, we may contact t he participant’s place of work, health care providers, case 
workers/social workers, or substance use treatment programs that they attend by [CONTACT_648]. The purpose of 
these  contacts  is solely  to assist  us in getting  in contact  [CONTACT_386448] 
(e.g., obtaining from these secondary contacts any new phone number information the participant may 
have); we will not be sharing any information about the study or the participants with these contacts. The 
timeline provided is  suggested, but exact dates may deviate depending on circumstances such as how 
difficult it is to contact [CONTACT_2299]. Strict time windows will not be mandated for intermediate contacts, 
though  all attempts  will be made  for these  contacts  to occur  with timing  as close  to that outlined  in the flow 
chart  as possible.  This is appropriate  for a feasibility  study  and dates  of all follow -up contacts  and attempts 
at contacts will be recorded on REDCap (see ED-Home Tracking Form ) and a summary Excel tracking 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  22 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484263] with providers, and necessary follow -up steps; no protected health information will be 
recorded  on the Excel tracking log.  
 
Intermediate Contact 1 (Day 7 –10) 
• Confirm participant contact  [CONTACT_3031].  
• Confirm 6 month follow -up visit date.  
• Ascertain whether referrals successful. If unsuccessful troubleshoot and decide next  steps.  
 
Intermediate Contact 1.2 (as needed, 7 –[ADDRESS_484264] 1)  
• Only for participants in whom referrals were  unsuccessful.  
• Ascertain  whether  participant  received  services  to which  referred.  If unsuccessful  troubleshoot 
and decide next  steps.  
 
Intermediate Contact 1.3 (as needed, 7 –[ADDRESS_484265] 1.2)  
• Only for participants in whom referrals were  unsuccessful.  
• Ascertain  whether  participant  received  services  to which  referred.  If unsuccessful  troubleshoot 
and decide next  steps.  
 
Intermediate Contact 2 (3 months after baseline)  
• Confirm participant contact  [CONTACT_3031].  
• Confirm [ADDRESS_484266] 3 (5 months after baseline)  
• Confirm participant contact  [CONTACT_3031].  
• Confirm 6 month follow -up visit date.  
• Mail participant 6 -month follow -up visit reminder  letter.  
 
7.3.4  Final Study  Visit  
The final study visit will be the 6 month follow -up visit. The procedure for participants who do not come to 
the follow -up visit is documented  in the ED-Home  Follow -Up Procedures  Flow  Chart  in the Study  Schematic 
Section.  
 
Final Study Visit (6 months, window -2 weeks to +8 weeks)  
• Complete 6 month follow -up survey (see instruments as listed in Section  7.1.1).  
• Participant is reminded that this is the final study visit. Participant is thanked for his/her time and 
has the opportunity to ask any questions about the  study.  
• Participant given $50 (cash or gift -card) follow -up reimbursement.  
 
7.3.[ADDRESS_484267]  it will be documented  in 
the follow -up log in REDCap.  
 
7.4 Concomitant Medications, Treatments, and  Procedures  
Not applicable.  
 
7.5 Justification for Sensitive  Procedures  
Not applicable.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  23 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 7.5.1  Precautionary Medications, Treatments, and Procedures  
Not applicable.  
7.6 Prohibited Medications, Treatments, and Procedures  
Not applicable.  
 
7.7 Prophylactic Medications, Treatments, and Procedures  
Not applicable.  
 
7.8 Participant Access to Study Intervention at Study  Closure  
Participants will still be able to access all existing community/social services for which they are eligible 
and ED/health care at the end of the study as they would if they had not participated in the study.  
 
8 Assessment of  Safety  
8.1 Specification of Safety Parameters  
This is an extremely low -risk study given the nature of the intervention (referrals to established social 
services).  As such,  study  endpoints  do not include  safety  parameters.  Since  the study  includes  participants 
with social and medical risks including housing instability and homelessness, we expect that some 
participants will worsen in status during the course of the study unrelated to the study. Though we will 
document and respond to any adverse eve nts that we become aware of during the study as described 
below,  we are not performing  explicit  investigations  to attempt  to discover  adverse  events  since  such  events 
are not expected related to the study. For example, we are not tracking diagnostic test results. We are not 
tracking  hospi[INVESTIGATOR_386389]-time.  Information  about  hospi[INVESTIGATOR_386390],  but such  stays  will not be considered  adverse  events.  
 
8.1.1  Definition of Adverse Events (AE)  
Required  text: An adverse  event  (AE) is any symptom,  sign,  illness  or experience  that develops  or worsens 
in severity during the course of the study. Intercurrent illnesses or injuries should be regarded as adverse 
events.  Abnormal  results  of diagnostic  procedures  are considered  to be adverse  events  if the abnormality:  
• results in study  withdrawal.  
• is associated with a serious adverse  event.  
• is associated with clinical signs or  symptoms.  
• leads to additional treatment or to further diagnostic  tests.  
• is considered by [CONTACT_137032].  
 
Study specific text: For the purpose of this study, the following events will not be reported as AEs:  
• Mild unrelated  event.  
• Moderate unrelated event. This would typi[INVESTIGATOR_386391], cold, 
etc. that were considered unrelated to study  participation.  
• Substance use events, including:  
o Worsening of substance  use 
o Need for higher level of  care 
o Signs and symptoms of substance use  withdrawal  
o Drug or alcohol  craving  
o Medical events that are directly related to substance  use 
 
8.1.2  Definition of Serious Adverse Events (SAE)  
Serious Adverse Event  
Required text: Adverse events are classified as serious or non -serious. A serious adverse event is any 
AE that is:  
• fatal 
• life-threatening  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  24 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 • requires or prolongs hospi[INVESTIGATOR_41836] 
• results in persistent or significant disability or  incapacity  
• a congenital anomaly or birth  defect  
• an important medical  event  
 
Important medical events are those that may not be immediately life threatening, but are clearly of major 
clinical significance. They may jeopardize the subject, and may require intervention to prevent one of the 
other serious outcomes noted above. For example, drug overdose or abuse, a sei zure that did not result 
in in-patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would 
typi[INVESTIGATOR_15355].  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious 
adverse events . 
 
Study specific text: Given the population being enrolled in the study, it is expected  that most participants 
will continue to have substance use (drug and alcohol), several may have overdose, and many may have 
hospi[INVESTIGATOR_170221] o ther treatments related to their substance use. These outcomes are being included in 
the 6 month follow -up assessment for exploratory analyses. When we learn about these outcomes at the 
time of follow -up assessments they will not be considered AEs/SAEs, bu t rather will be analyzed as for 
other exploratory study outcomes. We do not expect to learn about these outcomes in the interim (during 
the study  before  the 6 month  follow -up visit) because  we are not actively  tracking  participants’  clinical  status 
or health care  use. 
 
8.1.3  Definition of Unanticipated Problems  (UP) 
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected  in nature,  severity,  or frequency  (i.e., not described  in study -related  documents  such 
as the IRB -approved protocol or consent form, not expected events given the eligible study 
population,  etc.).  
• Related or possibly related to participation in the research  (i.e., possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_386449]).  
• Suggests that the research places subjects or others at greater risk of harm  (including  physical, 
psychological, economic, or social  harm).  
 
8.2 Classification of an Adverse  Event  
 
8.2.1  Severity of Event  
The following guidelines will be used to describe adverse event severity.  
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events  result  in a low level of inconvenience  or concern  with the therapeutic 
measures. Moderate events may cause some interference with  functioning.  
• Severe – Events interrupt a participant’s us ual daily activity and may require systemic drug 
therapy  or other  treatment.  Severe  events  are usually  potentially  life-threatening  or incapacitating.  
 
8.2.[ADDRESS_484268] their relationship to the study intervention/study participation 
assessed by [CONTACT_9154], with consultation from the IRB, study sponsor, and/or study DSMB as appropriate. 
Determinations will be made based on factors including considerations of causality based o n temporal 
relationships and clinical judgment. The degree of certainty about causality will be graded using the 
categories below:  
 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  25 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 • Definitely Related – There is clear evidence to suggest a causal relationship between study 
participation and the AE, which would not have occurred in absence of study  participation.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence of other 
factors is  unlikely.  
• Possibly Related – There is some evidence to suggest a causal re lationship (e.g., the event 
occurred within a reasonable time after administration of the trial intervention). However, other 
factors  may have  contributed  to the event  (e.g.,  the participant’s  clinical  condition,  other  concomitant 
events). Although an AE m ay rate only as “possibly related” soon after discovery, it can be flagged 
as requiring more information and later be upgraded to “probably related” or “definitely related,” as 
appropriate.  
• Unlikely to be Related – A clinical event unlikely based on temporality or clinical judgment to be 
related to the study. A temporal relationship to intervention administration may make a causal 
relationship improbable and/or there are other probable causes of the event (e.g., the participant’s 
clinical condition, o ther concomitant  treatments).  
• Not Related – The AE is completely independent of study intervention administration, and/or 
evidence exists that the event is definitely related to another  etiology.  
 
8.2.3  Expectedness  
The study PI [INVESTIGATOR_386392]. An AE will be 
considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk 
information previously described for the study intervention.  
 
8.3 Time Period and Frequency for E vent Assessment and  Follow -Up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits during 
study procedures as specified including participant surveys. Participants may also provide unsolicited 
information on AEs o r SAEs during study visits. Given the low -risk nature of this study, AEs will not be 
monitored after the final study visit (6 month follow -up visit).  
 
8.4 Reporting Procedures – Notifying the  IRB 
The PI [INVESTIGATOR_305097]:  
• AE or SAE AND unanticipated AND possibly, probably, or definitely related to the study. Study - 
specific descriptions of what will and will not be considered AEs or SAEs are provided in  Sections  
8.1.1 and 8.1.2.  
• Anticipated adverse events occurring with greater frequency than  expected.  
• Knowledge of any death of a study participant, even if determined unrelated to the  study.  
• Other unanticipated problems involving risks to study participants or  others.  
These events will be reported according to the NYU Langone Health IRB’s reporting guidelines.  
 
8.4.1 Adverse Event  Reporting  
AEs (see section 8.1.1) that are unanticipated and possibly/probably/definitely related to the study, or are 
occurring  with greater  frequency  than expected,  will be reported  to the IRB using  the appropriate  forms  via 
Research Navigator within [ADDRESS_484269] 
primary responsibility for reporting AEs, with assistance from the study  RC. 
 
8.4.2 Serious Adverse Event Reporting  
SAEs  (see section  8.1.2)  that are unanticipated  and possibly/probably/definitely  related  to the study,  or are 
occurring with greater frequency than expected, or any deaths of study participants will be reported to the 
IRB as quickly  as possible  after becoming  known  to the PI, and within  [ADDRESS_484270] primary responsibility 
for reporting AEs, with assistance from the study  RC. 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  26 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 8.4.3 Unanticipated Problem Reporting  
In addition to AE and SAE reporting as specified above, other unanticipated problems (UPs) involving 
risks to study participants or others will be reported to t he IRB within 72 business hours. UP reports will 
include the following information:  
• Protocol  identifying  information:  protocol  title and number,  PI’s name,  and the IRB project  number;  
• A detailed description of the event, incident, experience, or  outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an  UP; 
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the  UP. 
 
8.4.4 Reporting of  Pregnancy  
Not applicable; we are not testing participants for pregnancy.  
 
8.5 Reporting Procedures – Notifying the Study  Sponsor  
Adverse  Events  (AEs)  deemed  to be possibly,  probably,  or definitely  related  to the study  will be reported  to 
the NIDA PO at least once per year. At a minimum, this report will describe the event, when it occurred, 
and the outcome/resolution.  If there  were  no AEs,  a statement  that no AEs occurred  will be included  in the 
yearly progress report or communicated to the PO in writing. Serious Adverse Events (SAEs) are not 
expected but —if determined to be possibly, probably, or definitely related to the study —would be reported 
to the NIDA PO within [ADDRESS_484271] staff, planned follow up, whether participant will 
continue in the study, and any recommendations from the IRB. In addition, any negative IRB actions 
relevant to the study will be reported to the NIDA PO within 72  hours of the IRB  action.  
 
8.6 Reporting Procedures – Participating Investigators  
Not applicable (this is a single -center trial).  
 
8.[ADDRESS_484272] that this is a pi[INVESTIGATOR_386393].  
 
8.8 Safety Oversight  
This is an extremely low -risk study. The study has a small DSMB consisting of independent investigators 
(not otherwise affiliated with the study) who have the appr opriate expertise to advise on issues of study 
safety,  ethics,  and data management.  The DSMB  meets  once  yearly  to review  study  data and draft a report, 
which is sent to the study sponsor. The study sponsor has previously approved the DSMB process for the 
parent grant for this study (K23 DA039179). Additionally, any concerns or recommendations for changing 
or halting the study made by [CONTACT_386450]. 
 
DSMB members include:  
• [CONTACT_386465], Associate Professor, Department of Emergency  Medicine  
• [CONTACT_386466], Assistant Professor, Department of Population  Health  
 
It is the responsibility of the Principal Investigator [INVESTIGATOR_133605]. This safety monitoring 
will include careful assessment and appropriate reporting of adverse events as noted above.  
 
9 Clinical  Monitoring  
Given that this is an extremely low risk study that does not involve medical procedures or treatments, 
external clinical monitoring and/or independent audits are not appropriate. The study PI [INVESTIGATOR_386394]: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  27 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484273] of the following:  
• Baseline and follow -up participant surveys and other study  instruments.  
• Participant locator form information.  
• Information  collected  from follow -up/tracking  phone  calls and/or  NYULH  SendSafe  emails  with 
participants and/or applicable service providers, as previously  described.  
• Participant information extracted from approved external sources (with participant consent) 
including the Bellevue Hospi[INVESTIGATOR_386395].  
 
10.4 Description of Statistical Methods  
 
10.4.1  General Approach  
This is a single -arm pi[INVESTIGATOR_386396]. Methods appropriate for a feasibility study, including 
descriptive statistics, and simple bivariate and multivariable analyses will be used.  
 
10.4.2  Analysis of the Primary Efficacy  Endpoint(s)  
There are not primary efficacy endpoints for this study. Rather, the primary endpoints are measures of 
intervention/study fe asibility. The main analyses for feasibility will involve simple descriptive analyses 
examining endpoints including:  
• Number of patients approached, number (percent) screening positive for unhealthy alcohol or drug 
use, number (percent) screening positive f or homelessness  risk. 
• Number  (percent)  of those  approached  who are eligible  for the study.  Number  (percent)  reasons  for 
ineligibility.  
• Number (percent) of those eligible who agree to participate. Number (percent) reasons for  refusal.  
• Basic characteristics (e.g., gender, age, race, primary drug vs. alcohol use) of those who were 
eligible vs. ineligible and agreed and did not agree to participate using descriptive statistics and 
bivariate  analysis.  
• Number  and location  of referrals  made  for homelessness  prevention  and/or  substance  use services. 
Number  and types  of homelessness  prevention  and other  services  actually  received.  Length  of time 
between the ED intervention and receipt of  services.  
• Participant satisfaction and self -efficacy measures as assessed at baseline and 6 month follow -up 
visits.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  28 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 • Ability to contact [CONTACT_386451] -up time points (e.g., number of phone calls required, whether 
participant appeared for the 6 -month follow -up interview).  
 
We may also examine  for associations  between  participant  characteristics  and certain  feasibility  outcomes 
using bivariate and multivariable analyses as appropriate. For example, ability to contact [CONTACT_386452] -up visit may be exami ned by [CONTACT_386453] (e.g., type of substance  use).  
 
10.4.3  Analysis of the Secondary  Endpoint(s)  
Not applicable (there are not secondary endpoints).  
 
10.4.4  Safety Analyses  
Not applicable. AEs and SAEs will be recorded and reported as previously described.  
 
10.4.5  Adherence and Retention  Analyses  
Adherence and retention are key components of our primary feasibility endpoints. These analyses are 
described in Section 10.4.2.  
 
10.4.6  Baseline Des criptive  Statistics  
Simple descriptive statistics will be examined for baseline characteristics of study participants, as 
collected on the baseline study survey.  
 
10.4.7  Planned Interim Analysis  
Not applicable.  
 
[IP_ADDRESS]  Safety  Review  
Not applicable.  
 
[IP_ADDRESS]  Efficacy Review  
Not applicable.  
 
10.4.8  Additional Sub -Group Analyses  
There are no planned sub -group analyses for this feasibility study. Any sub -group analyses conducted on 
the basis of experience with the trial will be purely exploratory in nature.  
 
10.4.9  Multiple  Comparison/ Multiplicity  
Not applicable.  
 
10.4.10  Tabulation of Individual Response Data  
All planned analyses use aggregate data. Individual data will not be published.  
 
10.4.11  Exploratory Analyses  
Planned exploratory analyses will include examining new onset homelessness as measured by [CONTACT_386418] 
a homeless shelter within 6 months of the ED intervention (determined using the Department of Social 
Services CARES database), multiple self -reported housing status and substance use measures at the 6 - 
month follow -up interview compared to baseline, and measures of health services use. Although we are 
not powering the study to show statistically significant effects on these outcomes, we will be able to 
determine  feasibility  of outcome  measurement  and gain a preliminary  sense  of potential  intervention  effects 
which may help in determining sample size and other design considerations for future larger studies. 
Additional  exploratory  analyses  may be conducted  based  on stakeholder  interests  and feedback,  including 
as determi ned during yearly stakeholder  meetings.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  29 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484274] this 
goal can be accomplished by [CONTACT_124723] 40 ED patients, which will a llow us to try the 
intervention for a range of different types of patients and to encounter a wide array of issues to be 
considered for a future large trial. The enrollment goal of approximately 40 patients, which equates to 1 –2 
patients per week over 6 mo nths, is feasible. As this is a feasibility study only —not a study meant to test 
outcome effects —further sample size calculations are unnecessary and would be inappropriate.  
 
10.6 Measures to Minimize  Bias  
 
10.6.1  Enrollment/Randomization/Masking  Procedures  
Not applic able. This is a single -arm, non -randomized study; no blinding or masking is appropriate.  
 
10.6.2  Evaluation of Success of Blinding  
Not applicable. The study is not blinded.  
 
10.6.3  Breaking the Study Blind/Participant  Code  
Not applicable. The study is not blinded.  
 
11 Source Documents and Access to Source  Data/Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a clinical  
trial necessary  for the reconstruction  and evaluation  of the trial. Source  data are contained  in source 
documents. Original paper documents for the current study include: signed study consent forms, study 
reimbursement  receipts,  study  screening  and survey  assessments  (paper  forms  include  TLFBs  and WHO - 
ASSIST;  other  baseli ne and 6-month  assessments  will be maintained  on REDCap),  documentation  of study 
contacts including follow -up phone  calls.  
 
For paper forms, all entries should be printed legibly in black ink. If any entry error has been made, to 
correct  such  an error,  draw  a single  straight  line through  the incorrect  entry  and enter  the correct  data above 
it. All such  changes  must  be initialed  and dated.  Do not erase  or white  out errors.  For clarification  of illegible 
or uncertain entries, print the clarification  above the item, then initial and date it. For study information 
entered into REDCap, REDCap automatically keeps logs of all changes made in  forms.  
 
Access to study records will be limited to IRB -approved members of the study team. The investigator will 
permit study -related  monitoring,  audits,  and inspections  by [CONTACT_1201]/EC,  the sponsor,  government  regulatory 
bodies,  and University  compliance  and quality  assurance  groups  of all study  related  documents  (e.g. source 
documents, regulatory documents, data collection instruments, study data,  etc.).  
 
Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_28832].  
 
[ADDRESS_484275] quality assurance (QA) and quality control (QC).  
• All study staff, including RAs and RC, will be thoroughly trained both in overall GCP and human 
subjects protections and in study -specific  procedures.  
o Formal training will occur prior to the study beginning  recruitment.  
o Continuous training will occur in weekly staff team  meetings.  
• RAs will be closely supervised by [CONTACT_122440], with PI [INVESTIGATOR_113863]. The RC will be supervised by [CONTACT_32816]. 
• A SOP document will clearly outline all study procedures, including QA/QC  procedures.  
• Multiple QA/QC protections are built into REDCap data collection software being used for this 
study, including forced question entry (i.e., specified questions cannot be left blank), automatic 
logging  of all activities  in REDCap  including  any entry  changes,  and study  staff permission  rules.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  30 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 • All paper  forms,  including  consent  forms,  will be regularly  reviewed  (both  at the time of initial 
completion and at least weekly) for  completeness.  
• Weekly QA/QC reviews between the PI/RC will  include:  
o Review of numbers of patients approached, eligible/ineligible, refused,  participated.  
o Review to ensure that all eligibility classifications were made  correctly.  
o Review for  missing or out of range  data.  
o Review of any potential QA/QC issues identified by [CONTACT_305215] (which did 
not warrant more immediate  discussion).  
 
The PI [INVESTIGATOR_386397].  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_90471].  
 
13 Ethics/Protection of Human  Subjects  
13.[ADDRESS_484276]  
The protocol,  informed  consent  form(s),  recruitment  materials,  and all participant  materials  will be submitted 
to the IRB for review and approval. Approval of both the protocol and the consent form will be obtained 
before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_386454].  All changes  to the consent  form will be IRB approved; 
a determination  will be made  regarding  whether  previously  consented  participants  need  to be re-consented.  
 
13.3 Informed Consent Process  
In obtaining and documenting informed consent, the investigators will comply with applicable regulatory 
requirements in adherence to 45 CFR Part 46.  
 
13.3.1  Consent/Assent and Other Informational Documents Provided to  Participants  
Consent forms describing in detail the study inte rvention, study procedures, and risks are given to the 
participant and written documentation of informed consent is required prior to starting intervention. The 
written consent form was developed using the IRB -approved template and includes all required 
components.  In addition,  participants  will be given  a Simplified  Study  Information  Handout  that explains  the 
key points of the study in simple, easy to understand language. The following consent materials are 
submitted with this protocol: ED-Home Informed Co nsent  and ED-Home Key Information  Sheet.  
 
13.3.2  Consent Procedures and  Documentation  
Eligible patients will be invited to complete the written informed consent process in the ED. Multiple steps 
will be taken  to ensure  participant  privacy  during  the consent  process,  including:  asking  any visitors  to leave 
the area;  using  a private  room  or treatment  bay when  available  (many  of the treatment  areas  in the ED are 
private rooms with doors that close or single -patient bays with curtains that close, but if t he patient is not 
already in one of these locations patients can be moved to a more private area of the ED); research staff 
speaking in a quiet voice to avoid others overhearing the conversation. Informed consent is a process that 
is initiated prior to the  individual’s agreeing to participate in the study and continues throughout the 
individual’s study participation. Extensive discussion of risks and possible benefits of participation will be 
provided to potential participants. An IRB -approved key informati on form and informed consent document 
will be provided to patients and will also be verbally explained by [CONTACT_3665] (generally RC, though 
may include  the PI) and will detail,  in simple  and plain  language,  all study  procedures  and potential  risks of 
participating in the study. As part of the consent process, study staff will explain the purpose of the  study,  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  31 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484277] the area (though visitors will be allowed to stay for 
the consent process if preferred by [CONTACT_4317]). When feasible, research staff will also offer to move 
participants to a more private/quiet location of the ED.  
 
Participants will be invited to carefully review the full study informed consent document, and to ask any 
questions they might have. Potential participants will have the opportunity to discuss the s tudy with their 
surrogates or think about it prior to agreeing to participate. The participant and the person obtaining 
informed consent will sign and date two copi[INVESTIGATOR_386398]. One copy of the signed informed consent document will be given to 
the participant  for his/her  records  and the other  signed  copy  will be stored  with study  research  records  in a 
locked  file cabinet  in a locked  office.  Any alteration  to the standard  consent  process  and the justification  for 
such alteration will be  documented.  
 
Regular audits will be performed by [CONTACT_386455].  
 
Participant capacity and comprehen sion: Potential participants will be required to demonstrate adequate 
comprehension of the study and decision -making capacity to participate in the study. Only patients who 
have  the capacity  to give informed  consent  will be included  in the study.  Patients  will not be included  if they 
are too acutely intoxicated to give informed consent or otherwise medically unfit to participate, as 
determined by [CONTACT_386456]. If there is any question about the patient’s capacity 
to provi de informed consent, study staff will: a) ask ED care providers (e.g., physician, nurse) for advice 
about whether the participant has capacity to provide consent, and/or b) complete formal assessment of 
decisional capacity for participation in research usi ng the University of [LOCATION_004], San Diego Brief 
Assessment of Capacity to Consent (UBACC). The UBACC has been previously validated and used for 
studies at Bellevue Hospi[INVESTIGATOR_307], and generally takes less than [ADDRESS_484278] access to study data. The only paper 
documents containing identifying information that will be maintained are participant signed consent forms, 
Homebase  referral  form,  and 6-month  reminder  letter.  These  forms  will be stored  in a locked  file cabinet  in 
the PI’s locked  office.  Other  documents  including  any paper  survey  instruments  (such  as TLFBs  and WHO - 
ASSIST)  will not contain  participant  signatures  or other  participant  identifying  information  aside  from unique 
non-identifying participant ID numbers. Participants will be informed of the procedures that will be used to 
protect  their confidentiality  during  the informed  consent  process,  and questions  will be answered  to ensure 
they are comfortable sharing personally identifying information and answering potentially sensitive 
questions.  The collection  and use of patient  identifying  data will be minimized,  and the study  will use unique 
participant ID numbers tha t are assigned by [CONTACT_386457]. Identifying data will be 
destroyed  as soon  as feasible,  and de-identified  data will be used  whenever  possible  for data analysis.  Any 
downloaded  participant  identifying  information  will be stored  in a separate  file from participant  survey  results 
to minimize risks of associating identifying information with survey  responses.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  32 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 All research  assistants  and others  involved  in the study  will be required  to complete  appropriate  IRB Human 
Subjects and HIPAA trainings. The PI [INVESTIGATOR_386399]’ confidentiality protection measures. Any potential breaches of 
confidentiality  will be reported  to the study PI, who will report  such  breaches  to the IRB and any appropriate 
regulatory and funding agencies, and take any further corrective measures as appropriate. Study findings 
will be presented using only aggregate data; no publication or presentation will inv olve use of any 
individually identifying  information.  
 
Participants will provide informed consent to evaluate the exploratory outcome of homeless shelter entry 
using the NYC Department of Social Services (DSS) CARES database. The minimum possible participant 
identifying  information  will be provided  to allow  the appropriate  NYC  agency  to share  participant  shelter  use 
outcomes with the study team, only for participants who have been referred to their Homebase program 
and who have provided informed co nsent. For any other data linkage with CARES procedures will be 
outlined in a formal Memorandum of Understanding signed by [CONTACT_386458].  
 
Upon request only, the PI [INVESTIGATOR_386400]/or IRB for pur poses of 
study monitoring and assurance with applicable regulations.  
 
Information about study participants will be kept confidential and managed according to the requirements 
of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Those  regulations require a 
signed participant authorization informing the participant of the following:  
 
• What protected health information (PHI) will be collected from participants in this  study.  
• Who will have access to that information and  why. 
• Who will use o r disclose that  information.  
• The rights of a research participant to revoke their authorization for use of their  PHI. 
 
In the event that a participant revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], 
retains the ability to use all information collected prior to the revocation of subject authorization. For 
participants that have revoked authorization to collect or use PHI, attempts should be made to obtain 
permission to collect at least vital status (i.e. that the subject is aliv e) at the end of their scheduled study 
period.  
 
Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents. No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the sponsor. The study monitor, other authorized 
representatives of the sponsor, or representatives of the IRB may inspect all documents and records 
required to be maintained by [CONTACT_20616] r. The clinical study site will permit access to such records.  
 
The study participant’s contact [CONTACT_9168]. At the 
end of the study,  all records  will continue  to be kept in a secure  location  for as long a period  as dictated  by 
[CONTACT_46202].  
 
To further protect the privacy of study participants, a Certificate of Confidentiality has been obtained from 
the NIH. This certificate protects identifiable research in formation from forced disclosure. It allows the 
investigator and others who have access to research records to refuse to disclose identifying information 
on research participation in any civil, criminal, administrative, legislative, or other proceeding, wh ether at 
the federal,  state,  or local level.  By [CONTACT_386459], Certificates of Confidentiality help achieve the 
research objectives and promote  participation in studies by [CONTACT_4205][INVESTIGATOR_110800]. There are limitations to Certificate of Confidentiality protections which are clearly outlined on 
study consent  forms.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  33 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484279] ultimate responsibility for overseeing data collection and management. The PI [INVESTIGATOR_197051], completeness, legibility, and timeliness of the data  reported.  
 
The majority of data collection will occur using REDCap on NYULH IT -managed tablet computers (iPads), 
which will be password protected. Access to REDCap will only be granted to approved study personnel, 
each of whom will have a unique user ID and password to be used when collecting data. RAs will each be 
assigned a unique  “data access group” in REDCap, meaning that each RA will only be allowed to see and 
edit the records that he/she initiates. Further, REDCap permissions and functionality will be restricted for 
RAs so that they do not have the ability to see other RAs’ rec ords, delete records, or change forms. In 
addition to these protections, REDCap has other functionality that will ensure data collected are complete 
and reliable, including data entry field limitations and forced responses to indicated questions. REDCap 
also automatically maintains an audit log of all REDCap activity, including any changes made to records 
and who has made  them.  All information  entered  into REDCap  is automatically  saved  in the NYULH  internal 
REDCap project, accessible only to approved study personnel. For QA monitoring and data analysis, 
REDCap  data will be downloaded  in the form of Excel  and/or  statistical  programming  software  files. These 
files will be password protected and saved in secure NYULH IT -managed network drive accessible only to 
the PI, RC, and any other approved  personnel.  
 
For data collected on paper forms ( Additional Baseline and Follow -up Questionnaires  and ED-Home  
Homebase Referral Form for Bellevue Pi[INVESTIGATOR_2268] ) as well as for paper consent forms and reimbursement receipts, 
documents will be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink 
only will be used to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, research  
staff will cross  out the original  entry with a single  line, and initial  and date the change.  All completed paper 
forms will be stored in a locked file cabinet in the PI’s locked office. Data collection paper forms will 
additionally  be scanned  and saved  electronically  in secure  NYULH  network  drive  folders  accessible  only to 
the PI, RC, and any other approved study  personnel.  
 
The PI [INVESTIGATOR_386401]/QC procedures outlined in Section 12. 
Further, all RAs will receive standard training in study procedures and will complete supervised shifts until 
they are fully competent in all study data collection. The RC and PI [INVESTIGATOR_305107] -time to answer 
any RA’s questions about data collection. Further, weekly study team meetings will be used to continuall y 
reinforce standards of good data collection and management.  
 
14.2 Study Records  Retention  
Study documents and data will be retained for the longer of 3 years after close out or 5 years after final 
reporting/publication. These documents and data will be retain ed for a longer period, however, if required 
by [CONTACT_427]. Personally identifying information will be destroyed as soon as possible and within 
three years from final study reporting/publication. It is the responsibility of the sponsor to inform the  
investigator when data and documents no longer need to be retained.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  34 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 14.3 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or SOP requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by [CONTACT_3483].  
 
These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4 .5.2, and  4.5.3.  
• 5.1 Quality Assurance and Quality Control, section  5.1.1.  
• 5.[ADDRESS_484280] be reported to the local IRB per their g uidelines. The site PI/study staff is responsible for 
knowing and adhering to their IRB requirements.  
 
14.[ADDRESS_484281] ultimate 
responsibi lity and decision -making  authority  regarding  the publication  plan.  The International  Committee  of 
Medical Journal Editors (ICMJE) guidelines for authorship will be followed. This study will comply with the 
NIH Public  Access  Policy,  which  ensures  that the public has access  to the published  results  of NIH funded 
research. It requires scientists to submit final peer -reviewed journal manuscripts that arise from NIH funds 
to the digital archive PubMed Central upon acceptance for  publication.  
 
15 Study Finances  
15.1 Funding Source  
The study is funded by [CONTACT_18121]/NIDA (K23 DA039179). The Principal Investigator, [CONTACT_386467], is the 
NIH/NIDA grant holder.  
 
15.[ADDRESS_484282] payment.  
 
Participants  will be given  $[ADDRESS_484283] at the completion of the baseline visit to facilitate their ability to participate in the follow -up visit. 
Participants  will be given  $50 after completion  of the 6-month  follow -up visit, including  completion  of the 6- 
month follow -up survey. For follow -up visits conducted in person, participants will receive $50 cash. For 
follow -up visits conducted over the phone, participants will receive a $[ADDRESS_484284]  been  used  in 
other  studies  with similar  patient  populations —including  other  studies  at Bellevue  Hospi[INVESTIGATOR_58578] —and for 
similar amounts of participant time. They are not expected to constitute undue inducement of patients to 
participate in the research or to continue beyond a point that they would have otherwise withdrawn. 
Participants have the right  to withdraw from the study without financial penalty. In other words, any 
reimbursement already distributed to the participant will not be  revoked.  
 
Participant reimbursement receipts will document the provision of the reimbursements made in cash. All 
payments made to participants using gift -cards will be tracked and reconciled on a monthly basis using a 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  35 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: [ADDRESS_484285] Payments will be used to document distribution of payments with all study participants 
which includes the following information: the Human Subject identifier, IRB approved protocol, amount 
disbursed, date of the disbursement, acknowledgment by [CONTACT_386460]/or receipt of funds 
(e.g. signature [CONTACT_77525]), acknowledgement  of distribution  (i.e. signature  [CONTACT_386464]  [INVESTIGATOR_386402]), and whether or not the human subject is an employee of  NYULH.  
 
[ADDRESS_484286] of the research is being overseen by [CONTACT_386461], Daniela Fazio. A team of research assistants —who are part of the Department of 
Emergency Medicine’s Research Associate Program —will be supervised directly by [CONTACT_247327]  (Daniela  Fazio),  with oversight  by [CONTACT_978] (Kelly  Doran).  There  is also a DSMB  for this study,  as 
described in Section 8.8. A stakeholder group consisting of leaders from relevant community service 
organizations, governmental/policy organizations, and the research team meets once yearly. At this 
meeting, the PI [INVESTIGATOR_386403].  
 
[ADDRESS_484287] with this study (patent ownership, royalties, or 
financial gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed 
by [CONTACT_21804] a Committee -sanctioned conflict management plan 
that has been reviewed and approved by [CONTACT_28833]. All NYULH 
investigators will follow the applicable conflict of intere st policies.       
 
 
 
 
 
 
 
 
 
 
 
 
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  36 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
  
16 References  
1. Corporation for Supportive Housing and National Alliance to End Homelessness. Ending family 
homelessness:  national  trends  and local system  responses.  Prepared  for the Bill & Melinda  Gates 
Foundation. Oct 2012.  
2. By[CONTACT_7943]  T. Research  Brief:  Housing  outcomes  of veterans  following  exit from the Supportive 
Services for Veteran Families (SSVF) Program. February 2014  2014.  
3. The [LOCATION_002] Conference of Mayors. Hunger and Homelessness Survey: A Statu s Report on 
Hunger and Homelessness in America's Cities. A 25 -City Survey. . Washington, D.C. December 
2013.  
4. Office of Special Needs Assistance Programs, Office of Community Planning and  Development,  
U.S. Department of Housing and Urban Development. Homelessness Prevention and Rapid Re - 
Housing Program (HPRP): Year 2 Summary. Feb 2013.  
5. Culhane  DP, Metraux  S, By[CONTACT_7943]  T. A prevention -centered  approach  to homelessness  assistance: 
a paradigm shift? Housing Policy Debate.  2011;21(2):295 -315. 
6. Burt MR, Pearson C, Montgomery AE. Community -wide strategies for preventing homelessness: 
recent evidence. J Prim Prev.  2007;28(3 -4):213 -228. 
7. Montgomery AE, Fargo JD, By[CONTACT_386462], Kane V R, Culhane DP. Universal screening for 
homelessness  and risk for homelessness  in the Veterans  Health  Administration.  Am J Public 
Health. 2013;[ADDRESS_484288]  2:S210 -211. 
8. Moran G, Semansky R, Quinn E, Noftsinger R, Koenig T. Evaluability assessment of discharge 
planning and the prevention of homelessness: final report Westat. Rockville,  Maryland;2005.  
9. Api[INVESTIGATOR_386404] J. A paradigm shift in housing and homeless services: applying the population and high - 
risk framework to preventing homelessness The Open Health Servicse and Policy Journal. 
2010;3:41 -52. 
10. Lindblom  EN. Preventing  Homelessness.  In: Baumohl  J, ed. Homelessness  in America.  Westport, 
CT: Oryx Press;  1996:187 -200. 
11. Rolston H, Geyer J, Locke G, Metraux S, Treglia D. Final Report: Evaluation of the Homebase 
Community Prevention Program. Abt Associates Inc.  ;2013.  
12. Montgomery AE, Metraux S, Culhane D. Rethin king homelessness prevention among persons 
with serious mental illness. Social Issues and Policy Review.  2013;7(1):58 -82. 
13. Shinn  M, Baumohl  J, Hopper  K. The prevention  of homelessness  revisited.  Analyses  of Social 
Issues and Public Policy.  2001:95 -127. 
14. National Center for Health Statistics. Emergency Department Visits.  
http://www.cdc.gov/nchs/fastats/ervisits.htm . Accessed  February  26, 2014.  
15. Gordon JA. The hospi[INVESTIGATOR_386405] a social welfare institution. Ann Emerg  Med.  
1999;33(3):[ADDRESS_484289]  RA. Where  health  and welfare  meet:  social  deprivation 
among patients in the emergency department. J Urban Health.  2001;78(1):104 -111. 
17. Morris DM, Gordon JA. The role of the emergency department in the care of homeless and 
disadvantaged populations. Emerg Med Clin North Am.  2006;24(4):839 -848. 
18. Tang N, Stein J, Hsia RY, Maselli JH, Gonzales R. Trends and characteristics of US emergency 
depa rtment visits, 1997 -2007. JAMA.  2010;304(6):[ADDRESS_484290] Sheet: EMTALA. .  
http://www.acep.org/content.aspx?id=[ZIP_CODE] . Accessed  Accessed  January  17, 2013  
20. Gundlapalli AV, Redd A, Carter ME, Palmer M, Peterson R, Samore MH. Exploring patterns in 
resource utilization prior to the formal identification  of homelessness in recently returned 
veterans. Studies in health technology and informatics.  2014;202:265 -268. 
21. Schanzer B, Dominguez B, Shrout PE, Caton CL. Homelessness, health status, and health care 
use. Am J Public Health.  2007;97(3):464 -469. 
22. Doran KM , Raven MC, Rosenheck RA. What drives frequent emergency department use in an 
integrated health system? National data from the Veterans Health Administration. Ann Emerg 
Med.  2013;62(2):151 -159. 
23. D'Amore  J, Hung  O, Chiang  W, Goldfrank  L. The epi[INVESTIGATOR_386406]. Acad Emerg Med.  2001;8(11):1051 -1055.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  37 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
 24. Ku BS, Scott KC, Kertesz SG, Pi[INVESTIGATOR_217528]. Factors associated with use of urban emergency 
departments  by [CONTACT_941] U.S. homel ess population.  Public  Health  Rep.  2010;125(3):398 -405. 
25. Bisgaier J, Rhodes KV. Cumulative adverse financial circumstances: associations with patient 
health status and behaviors. Health Soc Work.  2011;36(2):129 -137. 
26. Kersey  MA, Beran  MS, McGovern  PG, Biros  MH, Lurie  N. The prevalence  and effects  of hunger 
in an emergency department patient population. Acad Emerg Med.  1999;6(11):[ADDRESS_484291] J Emerg Med.  2013;14(3):253 -262. 
28. Sullivan AF, Clark S, Pallin DJ, Camargo CA, Jr. Food security, health, and medication 
expenditures of emergency department patients. J Emerg Med.  2010;38(4):524 -528. 
29. Hankin A , Daugherty M, Bethea A, Haley L. The Emergency Department as a prevention site: a 
demographic analysis of substance use among ED patients. Drug Alcohol Depend. 2013;130(1 - 
3):230 -233. 
30. Substance Abuse and Mental Health Services Administration, Drug Abuse W arning Network, 
2011: National Estimates of Drug -Related Emergency Department Visits. HHS Publication No. 
(SMA) 13 -4760, DAWN Series D -39. Rockville, MD: Substance Abuse and Mental Health 
Services Administration, 2013.  . 
31. Bernstein SL, D'Onofrio G. A promising approach for emergency departments to care for patients 
with substance use and behavioral disorders. Health Aff (Millwood).  2013;32(12):2122 -2128.  
32. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disa bility, and comorbidity of 
DSM -IV alcohol abuse and dependence in the [LOCATION_002]: results from the National 
Epi[INVESTIGATOR_7446]. Arch Gen Psychiatry. 2007;64(7):830 - 
842. 
33. Compton WM, Thomas YF, Stinson FS, Grant BF. Pr evalence, correlates, disability, and 
comorbidity  of DSM -IV drug abuse  and dependence  in the United  States:  results  from the 
national epi[INVESTIGATOR_273647]. Arch Gen Psychiatry. 
2007;64(5):566 -576. 
34. Rockett IR, Putnam SL, Jia H, Smith GS. Assessing substance abuse treatment need: a 
statewide hospi[INVESTIGATOR_386407]. Ann Emerg Med.  2003;41(6):802 -813. 
35. Koegel P, Sullivan G, Burnam A, Morton SC, Wenzel S. Utilization of mental health and 
subs tance  abuse  services  among  homeless  adults  in Los Angeles.  Med Care.  1999;37(3):[ADDRESS_484292] drug users: a double jeopardy explored. International Journal of 
Drug Policy. 2001;12(4):[ADDRESS_484293] among 
homeless  adults  in Alameda  County,  [LOCATION_004].  Am J Public  Health.  1997;87(2):[ADDRESS_484294] M. Health care need and utilization: a 
preliminary comparison of injection  drug users, other illicit drug users, and nonusers. Subst Use 
Misuse.  1999;34(4 -5):[ADDRESS_484295]  M, McCoy  HV. Satisfaction  with access  to health  care among  injection 
drug users, other drug users, and nonusers. J Behav Health Serv Res.  2002;29(2):189 -197. 
40. Cherpi[INVESTIGATOR_386408]. Drinking  Patterns  and Problems:  A Comparison  of Primary  Care  with the 
Emergency Room. Subst Abus.  1999;20(2):85 -95. 
41. D'Onofrio G, Fiellin DA, Pantalon MV, et al. A brief intervention reduces hazardous and harmful 
drinking in emergency department patients. Ann Emerg Med.  2012;60(2):181 -192. 
42. Bogenschutz  MP, Donovan  DM, Mandler  RN, et al. Brief intervention  for patients  with problematic 
drug use presenting in emergency departments: a randomized clinical trial. JAMA internal 
medicine.  2014;174(11):1736 -1745.  
Study Number: s18 -[ZIP_CODE] 
Version Date: 3/18/2020  38 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_156586]: 11 January 2019   
  
17 Attachments  
These documents are relevant to the protocol, but they are not considered part of the pro tocol. They are 
stored and modified separately. As such, modifications to these documents do not require protocol 
amendments.  
 
The following attachments are included:  
 
 
Attachment  A. Schedule of Events  
Attachment  B. ED-Home Baseline Screening and  Survey 
Attachment  C. ED-Home [ADDRESS_484296] and Sticker 
Attachment  M. Housing Resource  Sheet  
Attachment N.  Housing Risk Flyer  
Attachment  O. ED-Home Tracking  Form  
Attachment  P. ED-Home Follow -up Procedures Form 
Attachment  Q. ED-Home Follow -up Visit Reminder Letter 
Attachment  R. ED-Home Email Template for Homebase 
Attachment  S. ED-Home EMR Data Abstraction  Tool 
 
 Study  Number:  s18-[ZIP_CODE]  1 
Version Date: 9/24/19 
Attachment A  
Schedule of Events  
 
 
 
 
 
Activity   
 
Baseline  
[Day 0]   
Intermediate 
Contact 1  
[Day 7 -10] Intermediate 
Contact 1.2  
[7-[ADDRESS_484297] 1, if 
needed]  Intermediate 
Contact 1.3  
[7-[ADDRESS_484298] 1.2, if 
needed]   
Intermediate 
Contact 2  
[3 months after 
Baseline]   
Intermediate 
Contact 3  
[5 months after 
Baseline]  Final Study Visit 
and Exploratory 
Outcomes  
[6 months after 
Baseline, window  
-2 to +8 weeks]  
Screening         
Screening questions  X       
Eligibility questions  X       
Verify inclusion/exclusion criteria  X       
Verify patient not already in study  X       
Informed consent process  X       
Survey         
ED-Home Survey (REDCap)  X      X 
Housing Risk Flyer        X 
NYC HRA YouTube video        X 
Additional baseline and follow -up questionnaires  X      X 
Participant information form  X       
Locator form  X       
Intervention         
Referral to and delivery of Bellevue substance use services  X       
Referral to Homebase services  X       
Troubleshoot unsuccessful Homebase referrals   X X X    
Follow -up Phone Calls         
Confirm participant contact [CONTACT_3031]   X   X X  
Confirm 6 -month follow -up visit date   X   X X  
Document successful Homebase referrals   X X X    
Additional Procedures         
Housing resource sheet (ineligible patients only)  X       
Homebase information sheet  X       
Schedule follow -up appointment  X       
Give study contact [CONTACT_386463]  X       
Reimbursement  X      X 
Send [ADDRESS_484299] Review        X 
 
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Health. Do not disclose or use except as authorized in writing by [CONTACT_305120]: 11 January 2019  